<DOC>
	<DOCNO>NCT02070211</DOCNO>
	<brief_summary>The purpose present trial investigate effect omega-3 PUFAs individual age 12-26 year 22q11DS ultra-high risk develop first episode psychosis .</brief_summary>
	<brief_title>Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids Patients With 22q11 Microdeletion Syndrome .</brief_title>
	<detailed_description>We use prospective , randomize , double-blind , placebo-controlled , single-centre study design . Eighty individual age 12-26 randomly assign two treatment condition ( 40 arm ) Department Neuroscience , Children Hospital Bambino Ges√π , Rome , Italy . Randomisation arrange Clinical Trials Department hospital . Participants receive 4 capsule ( 2 morning ; 2 evening ) period 12 week . The active treatment supplement yellow gelatine 0.625 g capsule contain concentrated marine fish oil . The daily dose 4 capsule provide approximately 700 mg eicosapentaenoic acid ( EPA , 20:5n3 ) , 480 mg docosahexaenoic acid ( DHA , 22:6n3 ) , 7.6 mg Vitamin E. Vitamin E add antioxidant fish oil capsule stabilize highly unsaturated fatty acid . Participants receive either 4 capsule 0.7g marine fish oil 4 capsule 0.7g paraffin oil ( absorbed gastrointestinal tract ) per day . The daily dose omega-3 PUFAs base previous trail ( Amminger et al. , 2010 ) . All patient receive standard treatment , include management psychiatrist resident psychiatrist non-neuroleptic pharmacotherapy clinically indicate . Specifically , Cognitive-behavioural therapy ( CBT ) embed within case management administer . The CBT base model develop PACE Clinic Melbourne , EDIE trial , Cologne , proven effective RCTs . The number session deliver captured client . In addition , fidelity monitor therapist rating session establish checklist therapeutic intervention . Any additional psychosocial intervention deliver also document . The case management component consist therapist address current interpersonal social issue provide practical help . 6 - 20 CBCM session provide within first 6 month . Hypotheses : 1 . Omega-3 PUFAs positive effect clinical course outcome UHR+22q11DS individual Specifically 12 month follow-up : - The transition psychosis rate significantly low omega-3 PUFA group - Ratings CAARMS , PANSS , MADRS , GAF improve significantly omega-3 PUFA group - Neuropsychological functioning significantly well omega-3 PUFA group . 2 . Lipid metabolism characteristic describe schizophrenia prevalent individual make transition psychosis - Reduced omega-3 PUFAs reduce nervonic acid ( Amminger et al. , 2011 ) increase PLA2 activity baseline characterize individual develop psychosis - PLA2 activity significantly decrease pre/post treatment omega-3 PUFA group</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>22q11 Deletion Syndrome</mesh_term>
	<criteria>write informed consent ( individual 18 write informed consent parent require ) ; age 12 26 year ; UHR classify CAARMS ( Yung et al. , 2005 ) ; genetic diagnosis 22q11DS acute suicidal behaviour ( score 6 CAARMS item 7.3 ) aggressive behaviour ( score 6 CAARMS item 5.4 ) ; Drug abuse contribute decisively presentation index episode , ( dependency morphine , cocaine , amphetamine , THC ) ; Alcohol abuse consider major problem ; Epilepsy ; 5./IQ &lt; 70 ) ; Pregnancy lactation ; Previous history antipsychotic drug treatment ( &gt; one week treatment ) ; Laboratory value 15 % outside normal range transaminase , CRP bleed parameter ; Individuals organic brain syndrome ; Individuals take anticoagulant ; Individuals take omega3 supplement , currently within 8 week include trial ; Individuals , severe , intercurrent illness opinion investigator may put risk influence result trial .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Psychotic Disorder</keyword>
	<keyword>22q11 Deletion Syndrome</keyword>
	<keyword>Fatty Acids , Omega-3</keyword>
</DOC>